Homepage0460 • HKG
add
Sihuan Pharmaceutical Holdings Group Ltd
Vorige slotkoers
$Â 1,31
Dag-range
$Â 1,30 - $Â 1,34
Jaar-range
$Â 0,63 - $Â 1,92
Beurswaarde
12,07Â mld. HKD
Gem. volume
28,51Â mln.
Koers/winst
58,41
Dividendrendement
1,65%
Primaire beurs
HKG
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (CNY) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 735,90Â mln. | 54,70% |
Bedrijfskosten | 386,99Â mln. | -22,90% |
Netto inkomsten | 38,55Â mln. | 142,07% |
Netto winstmarge | 5,24 | 127,21% |
Winst per aandeel | — | — |
EBITDA | 185,33Â mln. | 232,48% |
Effectief belastingtarief | 54,19% | — |
Balans
Totale activa
Totale passiva
| (CNY) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 3,98Â mld. | 9,48% |
Totale activa | 11,63Â mld. | 10,45% |
Totale passiva | 4,73Â mld. | -15,24% |
Totaal aandelenvermogen | 6,90 mld. | — |
Uitstaande aandelen | 9,04 mld. | — |
Koers-boekwaardeverhouding | 2,02 | — |
Rendement op activa | 2,91% | — |
Rendement op kapitaal | 4,30% | — |
Kasstroom
Nettomutatie in liquide middelen
| (CNY) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 38,55Â mln. | 142,07% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province. The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.
Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease. The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan. Wikipedia
CEO
Opgericht
2001
Website
Werknemers
2.843
